Biomedical engineers at the University of Melbourne have unveiled a groundbreaking 3D bioprinter capable of replicating complex human tissue structures, from soft brain matter to tough cartilage and bone. This advanced bioprinting system offers cancer researchers a powerful tool for creating accurate tissue models, which may dramatically improve the precision and ethical standards of drug discovery by reducing the reliance on animal testing.
Associate Professor David Collins, Head of the Collins BioMicrosystems Laboratory, explains, “Our technology not only accelerates the printing speed but allows precise cell positioning within the printed tissue. Current 3D bioprinters rely on cells naturally aligning without guidance, which often leads to inaccuracies in replicating human tissue. By utilizing acoustic waves generated by a vibrating bubble, our system organizes cells in a way that closely mimics natural tissue structure.”
Traditional 3D bioprinters use a slow, layer-by-layer approach that compromises cell viability and requires delicate handling to transfer the printed structures for analysis. The University of Melbourne team has revolutionized this by developing an optical-based system that uses vibrating bubbles, enabling them to print cellular structures in seconds—around 350 times faster than existing methods. This swift process not only enhances cell survival rates but also eliminates the need for physical handling, preserving the integrity and sterility of the structures.
PhD student Callum Vidler, lead author of the study, highlighted the technology’s transformative potential: “Bioprinting has long been limited by low output. Our advancements in speed, precision, and consistency bridge the gap between lab research and clinical application. Researchers from top institutions, including Harvard Medical School and the Sloan Kettering Cancer Centre, have expressed strong enthusiasm for its potential impact.”
This high-speed bioprinting innovation may pave the way for more efficient drug development and personalized medicine, setting a new standard for the biomedical research industry.
